

CHAPTER ONE: INTRODUCTION	1
STUDY GOAL AND OBJECTIVES	1
REASONS FOR DOING THE STUDY	2
INTENDED AUDIENCE.....	2
SCOPE OF REPORT	3
INFORMATION SOURCES AND METHODOLOGY.....	3
ANALYST'S CREDENTIALS.....	4
RELATED BCC RESEARCH REPORTS.....	4
BCC ONLINE SERVICES.....	4
DISCLAIMER	5
 CHAPTER TWO: EXECUTIVE SUMMARY.....	 6
EXECUTIVE SUMMARY.....	6
<i>SUMMARY TABLE CURRENT ANTIBIOTICS AND NEW PRODUCTS</i> <i>IN THE GLOBAL MARKET, THROUGH 2014 (\$ BILLIONS)</i>	 7
<i>SUMMARY FIGURE GLOBAL ANTIBIOTICS MARKET BY PRODUCT</i> <i>CLASSES, 2009 (%)</i>	 7
 CHAPTER THREE: OVERVIEW	 8
MICROBIOLOGY OF INFECTION.....	8
ANTIBIOTICS AND THE PROBLEM OF ANTIBIOTIC RESISTANCE.....	8
<i>TABLE 1 ANTIBIOTIC DISCOVERY AND RESISTANCE</i> <i>DEVELOPMENT</i>	 9
BACTERIA: CLASSIFICATION, IDENTIFICATION, AND RESISTANCE STATUS OF VARIOUS CLASSES	9
GRAM POSITIVE BACTERIA	10
<i>Bacillus Anthracis</i>	10
<i>Clostridium</i>	10
<i>C. Botulinum</i>	10
<i>C. Difficile</i>	11
<i>C. Perfringens</i>	11
<i>C. Tetani</i>	11
<i>Corynebacterium Diphtheriae</i>	11
<i>Enterococci</i>	12
<i>Erysipelothrix Rhusiopathiae</i>	12
<i>Nocardia Asteroides</i>	12
<i>Pneumococcus</i>	13
<i>Staphylococcus</i>	13
<i>Streptococcus</i>	14
GRAM-NEGATIVE BACTERIA	14
<i>Bordetella Pertussis</i>	15
<i>Brucella</i>	15
<i>Campylobacter</i>	15
<i>Enterobacteriaceae</i>	16
<i>Cedecea</i>	16

	<i>Citrobacter</i>	16
	<i>Enterobacter</i>	16
	<i>Escherichia coli</i>	16
	<i>Klebsiella</i>	17
	<i>Salmonella</i>	17
	<i>Shigella</i>	17
	<i>Haemophilus</i>	18
	<i>Neisseria</i>	18
	<i>Vibrio cholerae</i>	19
	MYCOBACTERIA	19
	<i>Mycobacterium Tuberculosis</i>	20
TABLE 2	U.S. TUBERCULOSIS CASES AND DEATHS, 1998–2007	20
	<i>Mycobacterium Leprae</i>	21
	<i>Mycobacteria other than Tuberculosis (MOTT)</i>	21
	SPIROCHETES	21
	<i>Borrelia Burgdorferi</i>	22
	<i>Treponema Pallidum</i>	22
	PATHOGEN DISEASE DISTRIBUTION	22
TABLE 3	ESTIMATED DISEASE INCIDENCE BY BACTERIA IN	
	SELECTED COUNTRIES, 2007	22
	COMPARISON OF NOCOSOMIAL AND COMMUNITY	
	INFECTIONS	23
	Hospital-Acquired (HA)-MRSA	23
	Community-Associated (CA)-MRSA	23
	NATURAL DEFENSES PRESENT IN THE COMBAT OF	
	INFECTION	24
	ANTISEPTICS	24
	BACTERIA AND OTHER MICROORGANISMS OF THE	
	DIGESTIVE TRACT	25
	CLASSIFICATION OF ANTIBIOTICS	25
	BACTERICIDAL AND BACTERIOSTATIC	26
	CLASSIFICATION BASED ON STRUCTURE	26
	Penicillins	26
	Cephalosporins	27
	Fluoroquinolones	27
	Tetracyclines	28
	Macrolides	28
TABLE 4	COMMONLY USED ANTIBIOTICS BY CLASS	29
	CLASSIFICATION BASED ON THE MODE OF ACTION OF	
	ANTIBIOTICS	29
	Cell Wall Inhibitors	29
	Cell Membrane Inhibitors	30
	Nucleic Acid Inhibitors	30
	Protein Synthesis Inhibitors	30

<i>TABLE 5 COMMONLY USED PROTEIN SYNTHESIS INHIBITORS</i>	31
Metabolic Inhibitors	31
Fatty Acid Biosynthesis (Fab) Inhibitors	31
ADMINISTRATION OF ANTIBIOTICS.....	32
DETERMINING THE POTENCY OF ANTIBIOTICS.....	32
ANTIBIOTIC SUSCEPTIBILITY TESTING.....	32
DRUG RESISTANCE: THE GREATEST CHALLENGE FACING THE ANTI-INFECTIVE DRUG MARKET	33
THE HISTORY OF ANTIBIOTIC RESISTANCE.....	33
CURRENT CRISIS OF ANTIBIOTIC RESISTANCE	34
THE MICROBIOLOGY OF ANTIBIOTIC RESISTANCE.....	34
MECHANISMS OF RESISTANCE DEVELOPED BY VARIOUS BACTERIA.....	35
Enzymatic Deactivation or Modification of Antibiotic	35
ESBL-Producing Organisms	35
Alteration of the Target Site of the Antibiotic.....	36
Alteration of the Metabolic Pathways	36
Reducing the Potential for Drug Accumulation	36
Biofilm Formation	37
<i>TABLE 6 HUMAN INFECTIONS INVOLVING BIOFILMS</i>	37
RESISTANCE IN GRAM-POSITIVE BACTERIA.....	37
Methicillin-Resistant <i>Staphylococcus Aureus</i> (MRSA)	38
Vancomycin-Intermediate <i>S. aureus</i> (VISA)	38
Vancomycin-Resistant <i>Enterococci</i> (VRE)	38
Multi-Drug-Resistant <i>Clostridium difficile</i>	39
RESISTANCE IN GRAM-NEGATIVE BACTERIA.....	39
Multi-Drug-Resistant <i>Acinetobacter Baumannii</i>	40
<i>Enterobacteriaceae</i> - (Resistance by ESBL and AmpC-beta Lactamase Production)	41
Resistance in <i>Pseudomonas Aeruginosa</i>	42
Tetracycline-Resistant, Penicillin-Resistant <i>Neisseria</i> <i>gonorrhoeae</i>	42
ANTIBIOTIC RESISTANCE IN MYCOBACTERIUM	42
<i>TABLE 7 MECHANISMS OF RESISTANCE BY BACTERIA REPORTED AGAINST VARIOUS ANTIBIOTIC CLASSES</i>	43
COST OF ANTIBIOTIC RESISTANCE.....	43
<i>TABLE 8 ECONOMIC PRESSURES DUE TO ANTIBIOTIC RESISTANCE, INSTITUTIONAL AND SOCIETAL</i>	44
EFFECTS OF INCREASING ANTIBIOTIC RESISTANCE.....	44
<i>TABLE 9 TREATMENT OPTIONS FOR RESISTANT BACTERIA</i>	45
<i>TABLE 9 (CONTINUED)</i>	46
ANTIBIOTIC STEWARDSHIP PROGRAMS IN HOSPITALS	46
<i>TABLE 10 ESSENTIAL COMPONENTS OF ANTIMICROBIAL STEWARDSHIP PROGRAMS</i>	47

TRENDS IN GEOGRAPHIC DISTRIBUTION OF RESISTANCE	47
Europe	48
U.S.	48
<i>TABLE 11 U.S. ANTIBIOTIC RESISTANCE TRENDS OF SOME</i>	
<i>CRITICAL INFECTIONS</i>	48
<i>TABLE 11 (CONTINUED)</i>	49
Global Epidemiology Trends of Antibiotic Resistance: Rest	
of the World	49
<i>TABLE 12 REST OF THE WORLD EPIDEMIOLOGY TRENDS OF</i>	
<i>ANTIBIOTIC RESISTANCE</i>	50
CHAPTER FOUR: REGULATORY TRENDS.....	51
POLITICS OF BACTERIAL RESISTANCE.....	51
AGRICULTURAL ANTIBIOTICS: REGULATORY TRENDS.....	51
<i>TABLE 13 U.S.-APPROVED AGRICULTURAL ANTIMICROBIALS</i>	51
<i>TABLE 14 AGRICULTURAL ANTIBIOTICS THAT CAN CROSS-</i>	
<i>SELECT ANTIBIOTICS USED TO TREAT HUMANS</i>	52
<i>TABLE 15 COMMON ANTIBIOTICS IN USE IN LIVESTOCK AND</i>	
<i>HUMANS</i>	53
REGULATORY ACTIONS AGAINST LARGE-SCALE USE OF	
AVOPARCIN	54
<i>TABLE 16 REGULATORY ACTIONS TAKEN BY GOVERNMENTS TO</i>	
<i>CONTROL AGRICULTURAL USE OF AVOPARCIN</i>	55
PREVALENCE OF FLUOROQUINOLONE RESISTANCE DUE	
TO AGRICULTURAL USAGE.....	55
<i>TABLE 17 FLUOROQUINOLONES USED IN AGRICULTURE</i>	56
<i>TABLE 18 U.S. REGULATORY ACTIONS CONTROLLING</i>	
<i>AGRICULTURAL USE OF FLUOROQUINOLONES</i>	56
INTERNATIONAL EFFORTS TO ADDRESS MICROBIAL	
RESISTANCE.....	57
ACTION ON ANTIBIOTIC RESISTANCE (REACT).....	57
ALLIANCE FOR THE PRUDENT USE OF ANTIBIOTICS	
(APUA)	57
EFFORTS BY THE WORLD HEALTH ORGANIZATION	
(WHO).....	57
<i>TABLE 19 ANTIBIOTICS OF CRITICAL IMPORTANCE TO HUMAN</i>	
<i>MEDICINES CATEGORIZATION BY THE WORLD HEALTH</i>	
<i>ORGANIZATION</i>	58
REGULATORY TRENDS IN U.S.....	58
<i>TABLE 20 U.S. REGULATORY BODIES AND OTHER AGENCIES</i>	
<i>INVOLVED IN MONITORING AGRICULTURAL ANTIBIOTICS</i>	59
Role of the FDA.....	59
Impact of Regulations on Innovation.....	60
EFFORTS BY EUROPEAN REGULATORY AGENCIES	60

European Centre for Disease Prevention and Control (ECDC).....	60
European Food Safety Authority (EFSA).....	61
<i>TABLE 21 E.U. KEY INITIATIVES TOWARD CONTAINING ANTIBIOTIC RESISTANCE</i>	<i>61</i>
<i>TABLE 22 PROJECTS UNDER DG-SANCO ADDRESSING ANTIBIOTIC RESISTANCE</i>	<i>62</i>
<i>TABLE 22 (CONTINUED)</i>	<i>63</i>
REGULATORY TRENDS IN ASIA.....	63
Australia	64
China.....	64
India	64
Japan.....	65
South Korea	65
Taiwan.....	65
Taiwan (Continued)	66
CHAPTER FIVE: PRODUCTS	67
PRODUCTS TARGETED AT ANTIBIOTIC RESISTANCE	67
<i>TABLE 23 KEY PRODUCTS TARGETING ANTIBIOTIC RESISTANCE</i>	<i>67</i>
LEVAQUIN	68
ZOSYN/TAZOCIN	68
AVELOX	68
CUBICIN	68
ANTIBACTERIAL DRUGS IN DEVELOPMENT BY CLASS OF PRODUCT.....	69
BETA LACTAM ANTIBIOTICS.....	69
<i>TABLE 24 B-LACTAM ANTIBIOTICS, IN DEVELOPMENT OR NEWLY INTRODUCED</i>	<i>69</i>
Doripenem.....	70
Tomopenem.....	70
PZ-601	70
Faropenem	71
Ceftaroline	71
Ceftobiprole.....	71
BAL-30072	72
FR-264205.....	72
<i>TABLE 25 B-LACTAM ANTIBIOTICS, IN DEVELOPMENT OR RECENTLY MARKETED</i>	<i>72</i>
<i>TABLE 25 (CONTINUED)</i>	<i>73</i>
FLUOROQUINOLONES	73
<i>TABLE 26 FLUOROQUINOLONE ANTIBIOTICS, IN DEVELOPMENT OR NEWLY INTRODUCED</i>	<i>74</i>
Sitafloxacin	74
Garenoxacin.....	74

Delafloxacin	74
WCK-771	75
Zabofloxacin	75
DC-159a	75
GLYCOPEPTIDES	75
<i>TABLE 27 GLYCOPEPTIDE ANTIBIOTICS, IN DEVELOPMENT OR NEWLY INTRODUCED</i>	76
Dalbavancin	76
Oritavancin	77
Telavancin	77
Ramoplanin	77
MACROLIDES	78
<i>TABLE 28 MACROLIDE ANTIBIOTICS, IN DEVELOPMENT OR NEWLY INTRODUCED</i>	78
Cethromycin	78
EDP-420	79
Fidaxomicin	79
OXAZOLIDINONES	79
<i>TABLE 29 OXAZOLIDINONE ANTIBIOTICS, IN DEVELOPMENT OR NEWLY INTRODUCED</i>	80
Radezolid	80
Torezolid	80
OTHER CLASSES OF ANTIBIOTICS IN PIPELINE	81
<i>TABLE 30 EMERGING CLASSES OF ANTIBIOTICS</i>	81
<i>TABLE 31 OTHER CLASSES OF ANTIBIOTICS, IN DEVELOPMENT OR NEWLY INTRODUCED</i>	81
<i>TABLE 31 (CONTINUED)</i>	82
<i>TABLE 31 (CONTINUED)</i>	83
Iclaprim	83
PTK 0796	84
AFN-1252	84
Friulimicin	84
Rifalazil	84
Pagibaximab	85
Nemonoxacin	85
Platensimycin	85
NXL-103	85
BC-3205 and BC-3781	86
PMX-30063	86
KBPA-101	86
KB-001	87
ACHN-490	87
CB-182804	87
VACCINES	87

<i>TABLE 32 VACCINES AGAINST BACTERIAL INFECTIONS IN DEVELOPMENT OR NEWLY INTRODUCED</i>	88
Menveo	88
Prevnar 13vPnC	89
Synflorix.....	89
V710	89
IC43.....	90
CHAPTER SIX: TECHNOLOGY TRENDS AND PATENT ANALYSIS	91
DECLINING TRENDS OF INNOVATION IN THE DEVELOPMENT OF NEW ANTIBIOTICS	91
<i>TABLE 33 U.S. FDA-APPROVED SYSTEMIC ANTIBACTERIAL NMES, 1983–2008</i>	91
BROAD-SPECTRUM VERSUS NARROW-SPECTRUM ANTIBIOTICS.....	91
<i>TABLE 34 SYSTEMIC ANTIBIOTICS TARGETING MRSA IN CLINICAL DEVELOPMENT</i>	92
<i>TABLE 34 (CONTINUED)</i>	93
<i>TABLE 35 ANTIBACTERIALS AGAINST MDR-GRAM-NEGATIVE BACTERIA IN CLINICAL DEVELOPMENT</i>	93
<i>TABLE 35 (CONTINUED)</i>	94
NEW FOCUS ON GRAM-NEGATIVE PATHOGENS	94
ANALOGUES OF EXISTING ANTIBIOTICS VS NOVEL MOLECULES/ TARGETS.....	95
<i>TABLE 36 ANALOGUES OF EXISTING DRUGS AND NEW MOLECULES</i>	95
CATIONIC PEPTIDES AS NEW GENERATION ANTIBACTERIALS FOR THERAPEUTIC USE	96
<i>TABLE 37 COMPARISON OF CATIONIC PEPTIDE ANTIBIOTICS AND CONVENTIONAL ANTIBIOTICS</i>	96
<i>TABLE 38 CATIONIC ANTIBACTERIAL PEPTIDES FOR SYSTEMIC ADMINISTRATION, UNDER DEVELOPMENT</i>	97
BACTERIAL INTERFERENCE: A NEW APPROACH FOR THE TREATMENT OF BACTERIAL INFECTIONS.....	97
BACTERIOPHAGE THERAPY.....	98
PATENT ANALYSIS	98
<i>TABLE 39 U.S. PTO-GRANTED PATENTS BY ANTIBIOTIC STRUCTURAL CLASSES, 1976–SEPTEMBER 8, 2009</i>	99
<i>TABLE 40 TRENDS IN PATENTING OF BIG PHARMA COMPANIES RELATED TO ANTIBIOTICS*</i>	100
<i>TABLE 41 PATENTS IN ANTIBIOTICS BY NEW AND EMERGING COMPANIES, 1976–SEPTEMBER 8, 2009</i>	100
<i>TABLE 41 (CONTINUED)</i>	101
CHAPTER SEVEN: INDUSTRY STRUCTURE	102
REVIVAL OF ANTIBIOTIC SECTOR.....	102

RISING PRESENCE OF BIOTECH COMPANIES	102
TABLE 42 <i>SELECTED BIOTECH ANTIBACTERIALS IN DEVELOPMENT</i>	102
TABLE 42 (CONTINUED).....	103
REVIVAL OF THE SECTOR WITH RENEWED INTEREST OF BIG PHARMA	103
TABLE 43 <i>RECENT INVESTMENTS OR PARTNERSHIPS BY BIG PHARMA COMPANIES TARGETING THE ANTIBIOTICS SECTOR</i>	103
TABLE 43 (CONTINUED).....	104
GLOBAL MARKET FOR ANTIBIOTICS AND FORECASTS.....	104
TABLE 44 <i>GLOBAL GROWTH TRENDS FOR CARBAPENEM ANTIBIOTICS, THROUGH 2014 (\$ MILLIONS)</i>	104
FIGURE 1 <i>GLOBAL GROWTH TRENDS FOR CARBAPENEM ANTIBIOTICS, 2008-2014 (\$ MILLIONS)</i>	105
TABLE 45 <i>GLOBAL GROWTH TRENDS FOR CEPHALOSPORIN ANTIBIOTICS, THROUGH 2014 (\$ MILLIONS)</i>	105
FIGURE 2 <i>GLOBAL GROWTH TRENDS FOR CEPHALOSPORIN ANTIBIOTICS, 2008-2014 (\$ MILLIONS)</i>	106
TABLE 46 <i>GLOBAL GROWTH TRENDS OF MACROLID ANTIBIOTICS, THROUGH 2014 (\$ MILLIONS)</i>	106
FIGURE 3 <i>GLOBAL GROWTH TRENDS OF MACROLID ANTIBIOTICS, 2008-2014 (\$ MILLIONS)</i>	107
TABLE 47 <i>GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS, THROUGH 2014 (\$ MILLIONS)</i>	107
FIGURE 4 <i>GLOBAL MARKET FOR BETA-LACTAM ANTIBIOTICS, 2008-2014 (\$ MILLIONS)</i>	108
TABLE 48 <i>GLOBAL MARKET FOR FLUOROQUINOLONES, THROUGH 2014 (\$ MILLIONS)</i>	108
FIGURE 5 <i>GLOBAL MARKET FOR FLUOROQUINOLONES, 2008-2014 (\$ MILLIONS)</i>	109
TABLE 49 <i>GLOBAL MARKET FOR BACTERIAL VACCINES, THROUGH 2014 (\$ MILLIONS)</i>	109
FIGURE 6 <i>GLOBAL MARKET FOR BACTERIAL VACCINES, 2008-2014 (\$ MILLIONS)</i>	110
TABLE 50 <i>GLOBAL ANTIBIOTIC MARKETS, THROUGH 2014 (\$ MILLIONS)</i>	111
FIGURE 7 <i>GLOBAL ANTIBIOTIC MARKETS, 2008-2014 (\$ MILLIONS)</i>	111
LEADING COMPANIES IN THE ANTIBIOTICS MARKET.....	112
TABLE 51 <i>TOP PLAYERS AND KEY PRODUCTS IN THE ANTIBIOTICS MARKET</i>	112
TABLE 51 (CONTINUED).....	113
COMPANY PROFILES	113
ACHAOPEN, INC.....	113
ADVANCED LIFE SCIENCES	113

AFFINIUM PHARMACEUTICALS	114
ARPIDA, LTD.....	115
BASILEA PHARMACEUTICA LTD.	115
BAYER SCHERING PLOUGH AG	116
BIOSYNEXUS INC.....	116
CUBIST PHARMACEUTICALS, INC.	116
ENANTA PHARMACEUTICALS.....	117
GLAXO SMITHKLINE PLC.....	117
<i>TABLE 52 GSK'S PIPELINE ANTIBIOTICS AND BACTERIAL VACCINE PRODUCTS</i>	<i>118</i>
<i>TABLE 52 (CONTINUED).....</i>	<i>119</i>
INTERCELL AG	119
<i>TABLE 53 INTERCELL AG'S ANTI-BACTERIAL PIPELINE PRODUCTS.....</i>	<i>120</i>
KALOBIOS PHARMACEUTICALS, INC.....	120
KENTA BIOTECH LTD.....	121
JOHNSON &JOHNSON.....	121
MERCK & CO. INC.....	122
MPEX PHARMACEUTICALS.....	122
NABRIVA THERAPEUTICS AG	123
NOVABAY PHARMACEUTICALS, INC.....	123
NOVARTIS INTERNATIONAL AG.....	124
<i>TABLE 54 NOVARTIS' BACTERIAL VACCINE PIPELINE.....</i>	<i>125</i>
NOVEXEL	125
OPTIMER PHARMACEUTICALS, INC.....	126
OSCIENT PHARMACEUTICALS CORPORATION.....	126
PARATEK PHARMACEUTICALS, INC.....	127
PFIZER, INC.	127
POLYMEDIX, INC.	128
REPLIDYNE, INC.....	129
RIB-X PHARMACEUTICALS, INC.	129
SANOFI-AVENTIS	130
<i>TABLE 55 SANOFI-AVENTIS'S BACTERIAL VACCINE CANDIDATES.....</i>	<i>131</i>
TAIGEN BIOTECHNOLOGY CO., LTD.....	131
THERAVANCE, INC.	131
TRIOUS THERAPEUTICS	132
WYETH PHARMACEUTICALS.....	132
<i>TABLE 56 WYETH'S ANTIBACTERIAL PIPELINE</i>	<i>133</i>
APPENDIX.....	134
<i>TABLE 57 ABBREVIATIONS.....</i>	<i>134</i>
<i>TABLE 57 (CONTINUED).....</i>	<i>135</i>
<i>TABLE 57 (CONTINUED).....</i>	<i>136</i>